ATE532791T1 - In der 8-stellung modifiziertes purin- nukleosidderivat und dessen medizinische verwendung - Google Patents

In der 8-stellung modifiziertes purin- nukleosidderivat und dessen medizinische verwendung

Info

Publication number: ATE532791T1
Authority: AT; Austria
Prior art keywords: group; modified; optionally substituted; useful; ring
Prior art date: 2004-09-17

Application number

AT05783540T

Other languages

English (en)

Inventor

Kazuya Tatani

Yoshinori Nonaka

Norihiko Kikuchi

Original Assignee

Kissei Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-17

Filing date

2005-09-14

Publication date

2011-11-15

2005-09-14 Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical

2011-11-15 Application granted granted Critical

2011-11-15 Publication of ATE532791T1 publication Critical patent/ATE532791T1/de

Links

150000003834 purine nucleoside derivatives Chemical class 0.000 title abstract 3
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 abstract 1
201000005569 Gout Diseases 0.000 abstract 1
201000001431 Hyperuricemia Diseases 0.000 abstract 1
206010046337 Urate nephropathy Diseases 0.000 abstract 1
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract 1
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract 1
230000005856 abnormality Effects 0.000 abstract 1
125000003277 amino group Chemical group 0.000 abstract 1
229910052801 chlorine Inorganic materials 0.000 abstract 1
125000001309 chloro group Chemical group Cl* 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
125000005843 halogen group Chemical group 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
125000003107 substituted aryl group Chemical group 0.000 abstract 1
125000003396 thiol group Chemical group [H]S* 0.000 abstract 1
229940116269 uric acid Drugs 0.000 abstract 1
208000008281 urolithiasis Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)

AT05783540T 2004-09-17 2005-09-14 In der 8-stellung modifiziertes purin- nukleosidderivat und dessen medizinische verwendung ATE532791T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2004270740		2004-09-17
PCT/JP2005/016894 WO2006030803A1 (ja)	2004-09-17	2005-09-14	８位修飾プリンヌクレオシド誘導体及びその医薬用途

Publications (1)

Publication Number	Publication Date
ATE532791T1 true ATE532791T1 (de)	2011-11-15

Family

ID=36060055

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05783540T ATE532791T1 (de)	2004-09-17	2005-09-14	In der 8-stellung modifiziertes purin- nukleosidderivat und dessen medizinische verwendung

Country Status (8)

Country	Link
US (1)	US7795236B2 (de)
EP (1)	EP1813623B1 (de)
JP (1)	JP4932488B2 (de)
AT (1)	ATE532791T1 (de)
CA (1)	CA2580236A1 (de)
ES (1)	ES2373668T3 (de)
TW (1)	TW200626609A (de)
WO (1)	WO2006030803A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPWO2006115137A1 (ja) *	2005-04-22	2008-12-18	キッセイ薬品工業株式会社	２−アミノベンズイミダゾール誘導体及びその医薬用途
MX2009004051A (es) *	2006-10-20	2009-05-11	Regeneron Pharma	Uso de antagonistas de il-1 para tratar gota y pseudo gota.
US20110171192A1 (en)	2008-09-05	2011-07-14	Hiroshi Tomiyama	Substituted amine derivative and medicinal composition comprising same as the active ingredient
US20130102652A1 (en) *	2010-03-23	2013-04-25	University Of Utah Research Foundation	Methods and compositions related to modified adenosines for controlling off-target effects in rna interference
EP3551611A1 (de)	2016-12-09	2019-10-16	Celtaxsys Inc.	Monamin- und monoaminderivate als inhibitoren der leukotrien a4-hydrolase
CN108329372B (zh) *	2017-01-20	2022-07-26	浙江省亚热带作物研究所	N6-(2-羟乙基)腺苷及其衍生物在制备治疗痛风药物中的应用
US11986480B2 (en)	2017-02-03	2024-05-21	Tohoku University	Heterocyclic compound

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6294522B1 (en) *	1999-12-03	2001-09-25	Cv Therapeutics, Inc.	N6 heterocyclic 8-modified adenosine derivatives
US20030008841A1 (en) *	2000-08-30	2003-01-09	Rene Devos	Anti-HCV nucleoside derivatives
US6727231B1 (en) *	2000-10-12	2004-04-27	Repligen Corporation	Uridine therapy for patients with elevated purine levels
GB2372741A (en) *	2001-03-03	2002-09-04	Univ Leiden	C2,8-Disubstituted adenosine derivatives and their different uses

2005
- 2005-09-14 WO PCT/JP2005/016894 patent/WO2006030803A1/ja not_active Ceased
- 2005-09-14 JP JP2006535162A patent/JP4932488B2/ja not_active Expired - Fee Related
- 2005-09-14 ES ES05783540T patent/ES2373668T3/es not_active Expired - Lifetime
- 2005-09-14 CA CA002580236A patent/CA2580236A1/en not_active Abandoned
- 2005-09-14 EP EP05783540A patent/EP1813623B1/de not_active Expired - Lifetime
- 2005-09-14 AT AT05783540T patent/ATE532791T1/de active
- 2005-09-16 TW TW094132030A patent/TW200626609A/zh unknown
2007
- 2007-03-13 US US11/717,741 patent/US7795236B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2006030803A1 (ja)	2006-03-23
EP1813623B1 (de)	2011-11-09
ES2373668T3 (es)	2012-02-07
US7795236B2 (en)	2010-09-14
EP1813623A1 (de)	2007-08-01
US20070179115A1 (en)	2007-08-02
CA2580236A1 (en)	2006-03-23
EP1813623A4 (de)	2010-08-18
JP4932488B2 (ja)	2012-05-16
US20100249054A9 (en)	2010-09-30
TW200626609A (en)	2006-08-01
JPWO2006030803A1 (ja)	2008-05-15

Publication	Publication Date	Title
NO20082090L (no)	2008-05-20	Pyridopyrimidinoninhibitorer av P13K alfa
SG170101A1 (en)	2011-04-29	2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
NO20071042L (no)	2007-04-19	5-substituerte 2-fenylaminobenzamider som MEK-inhibitorer
NO20073465L (no)	2002-12-12	Benzotiazol-derivater
MY147442A (en)	2012-12-14	Imidazoquinolines as lipid kinase inhibitors
NO20060981L (no)	2006-05-02	Pyridazinderivater og deres anvendelse som terapeutiske midler
MY148145A (en)	2013-03-15	Methods of synthesis and/or purification of diaminophenothiazinium compounds
WO2007110237A3 (en)	2008-06-12	Amide derivatives and their application for the treatment of g protein related diseases
NO20053748L (no)	2005-10-07	Pyrrolopyridazinderivater.
NO20081844L (no)	2008-05-29	Terapeutiske forbindelser
NO20084516L (no)	2009-01-13	Terfenylderivater for behandling av alzheimers sykdom
NO20092286L (no)	2009-08-13	Nitrogenhaldige heterosykliske forbindelser og anvendelse derav
GEP20104973B (en)	2010-04-26	Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
ATE384058T1 (de)	2008-02-15	Thiazolderivate
MY144928A (en)	2011-11-30	Benzofuran derivatives
ATE537181T1 (de)	2011-12-15	Benzimidazolderivate und deren medizinische verwendungen
EP2100895A4 (de)	2009-12-23	Tricyclische verbindung und deren medizinische verwendung
DE602004005502D1 (de)	2007-05-03	Comt-inhibitoren
ATE492534T1 (de)	2011-01-15	1h-indol-5-ylpiperazin-1-ylmethanonderivate
EP1813623A4 (de)	2010-08-18	In der 8-stellung modifiziertes purin-nukleosidderivat und dessen medizinische verwendung
NO20075209L (no)	2007-10-11	Substituerte aryl 1,4-pyrazinderivater
DE602006014022D1 (de)	2010-06-10	5-substituierte indol-2-carbonsäureamidderivate
MXPA05012369A (es)	2006-02-02	Derivados de benzotiazol y uso de los mismos en el tratamiento de enfermedades relacionadas con el receptor a2a de adenosina.
CY1108241T1 (el)	2013-09-04	Πυριδυλσουλφοναμιδο πυριμιδινες για την θεραπεια της διαβητικης νεφροπαθειας
ATE289812T1 (de)	2005-03-15	Azolylcarbynol-derivative von aryl (oder heteroaryl) zur behandlung von atemwegserkrankungen